Seven Network and chairman Kerry Stokes can challenge a ruling allowing Fairfax to access thousands of “deeply personal” emails sent to and from former soldier Ben Roberts-Smith during his defamation case.
A judge has expressed his preliminary view that cases brought in Queensland cannot be thrown out where the costs of the claims are disproportionate to their importance, allowing a defamation case by entrepreneur Robert McVicker against the ABC to proceed.Â
BlueScope Steel is challenging a ruling that it pay a record $57.5 million penalty for engaging in attempted price fixing with flat steel distributors.
Wealth management firm Findex can add new claims for damages in its long-running dispute with a former financial advisor who allegedly sent disparaging emails to clients and investors and brought his own claim in trespass after the company seized documents from his residence.Â
An appeals court has set aside findings of professional misconduct against a Perth solicitor who allegedly failed to pay a silk $23,000 in fees after finding a tribunal member had served on a chambersâ board with the senior barrister for eight years.Â
A judge has ordered National Australia Bank to pay just one-fifth the $10 million penalty proposed by ASIC for overcharging customer fees, taking aim at the regulator’s concise pleading and saying the maximum penalty he could order was âwoefully inadequateâ.
The Australian Competition and Consumer Commission has brought proceedings against EnergyAustralia for allegedly misleading consumers when notifying them of changes to electricity prices.Â
A judge has approved a common fund order awarding $6.88 million to the funder behind a class action against Fonterra that settled for $25 million, opting not to wait for a much-anticipated appeals court ruling on the power to make CFOs at settlement.
The corporate regulator has brought proceedings against the Australian arm of Kraken Crypto Exchange, alleging it breached design and distribution obligations for a margin trading product that has lost customers almost $13 million.
Indian generic drug maker Cipla has sued pharmaceutical giants Bristol-Myers Squibb and Pfizer alleging the patents behind their blockbuster deep vein thrombosis drug Eliquis are invalid.